Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Agabiti-Rosei

Showing results (1-10 of 194) with videos related to

Pageof 20
Sort By:
Blood Pressure|July 24, 2003
Assessment of preclinical target organ damage in hypertesion: left ventricular hypertrophyE Agabiti Rosei
Blood Pressure|July 24, 2003
Assessment of preclinical target organ damage in hypertension: carotid intima-media thickness and plaqueE Agabiti Rosei
Blood Pressure. Supplement|January 1, 1997
Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatmentE Agabiti-Rosei
Journal of Cardiovascular Pharmacology|January 1, 1994
Evaluation of the cardiac effects of antihypertensive agentsE Agabiti-Rosei
Journal of Cardiovascular Pharmacology|January 1, 1995
The cardiac and vascular effects of lacidipineE Agabiti-Rosei
Journal of Hypertension|January 16, 2002
Assessment of preclinical target organ damage in hypertension: left ventricular hypertrophyE Agabiti Rosei,
Blood Pressure. Supplement|January 1, 1996
Hypertension, atherosclerosis and LVH in ELSA. European Lacidipine Study of AtherosclerosisE Agabiti Rosei
Cardiologia (Rome, Italy)|August 1, 1997
[Genetic polymorphism of the renin-angiotensin system and cardiovascular diseases]M Castellano, E Agabiti-Rosei
Cardiologia (Rome, Italy)|December 25, 2002
[Significance and limits of dynamic monitoring of blood pressure in the clinical assessment of hypertensive patients]D Rizzoni, E Agabiti-Rosei
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology|September 19, 2000
[Indications for echocardiography in subjects with essential arterial hypertension]P Verdecchia, E Agabiti-Rosei
Pageof 20

Showing results (1-10 of 194) with videos related to

Sort By:
Pageof 20
Blood Pressure|July 24, 2003
Assessment of preclinical target organ damage in hypertesion: left ventricular hypertrophyE Agabiti Rosei
Blood Pressure|July 24, 2003
Assessment of preclinical target organ damage in hypertension: carotid intima-media thickness and plaqueE Agabiti Rosei
Blood Pressure. Supplement|January 1, 1997
Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatmentE Agabiti-Rosei
Journal of Cardiovascular Pharmacology|January 1, 1994
Evaluation of the cardiac effects of antihypertensive agentsE Agabiti-Rosei
Journal of Cardiovascular Pharmacology|January 1, 1995
The cardiac and vascular effects of lacidipineE Agabiti-Rosei
Journal of Hypertension|January 16, 2002
Assessment of preclinical target organ damage in hypertension: left ventricular hypertrophyE Agabiti Rosei,
Blood Pressure. Supplement|January 1, 1996
Hypertension, atherosclerosis and LVH in ELSA. European Lacidipine Study of AtherosclerosisE Agabiti Rosei
Cardiologia (Rome, Italy)|August 1, 1997
[Genetic polymorphism of the renin-angiotensin system and cardiovascular diseases]M Castellano, E Agabiti-Rosei
Cardiologia (Rome, Italy)|December 25, 2002
[Significance and limits of dynamic monitoring of blood pressure in the clinical assessment of hypertensive patients]D Rizzoni, E Agabiti-Rosei
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology|September 19, 2000
[Indications for echocardiography in subjects with essential arterial hypertension]P Verdecchia, E Agabiti-Rosei
Pageof 20